ABCA1 and early-onset autosomal dominant Alzheimer disease: CS treatment reduced Aβ pathology and improved memory in young male mice that express APOE3 but not in female APOE3 mice or mice that express APOE4. Therefore, levels of Aβ pathology may impact the ability of targeting only ABCA1 to be an effective Alzheimer’s disease therapeutic.